NR3C1 and Hypertension: The prevalence of patients exhibiting adrenal hyperplasia and hypertension and/or presenting hypercortisolism is 5% thus encouraging further GR mutation screening to differentiate GR resistance from Cushing’s syndromes and to improve the follow-up of these patients.